Building a Better Flu Vaccine--and Giving Chickens a Rest

Scientists move a step closer to making a seasonal flu preventative that can be produced quickly and does not require adapting a live flu virus seed to grow in eggs















Share on Tumblr

More In This Article

As vaccine-makers gear up for the winter flu season, one biotech company is reporting success with an alternative method of developing a flu preventative that it says could work more effectively and be produced more quickly than traditional inoculations prepared in fertilized chicken eggs.

This moves Rockville, Md.–based Novavax, Inc., a step closer to submitting its seasonal flu vaccine candidate to the U.S. Food and Drug Administration (FDA) for approval, and at the same time helping the company move forward with its efforts to develop a vaccine against the H1N1 "swine" flu. The company's vaccine approach in both cases is to use viruslike particles (VLPs) containing surface proteins that make the VLPs resemble a virus, thereby eliciting the proper immune response—even though the VLPs lack the genes needed to replicate themselves.

To prepare a vaccine made in fertilized chicken eggs, scientists crack the shell and inject the influenza virus into the fluid surrounding the embryo. Ideally, the embryo is infected and the virus multiplies. After several days of incubation the eggs are opened and the virus is removed, purified and used to make the vaccine, as a 2004 Scientific American article points out. (The VLP approach bypasses the steps needed to adapt virus strains to grow in eggs.)

There are, however, several drawbacks to this "chicken and egg" approach, which dates back more than 50 years. In order to produce 300 million doses of vaccine, egg-based production would require some 900 million eggs, according to the U.S. Department of Health and Human Services. An outbreak of avian flu in particular could put eggs in short supply, restricting the amount of vaccine that could be produced. In addition, vaccine-makers that use eggs cannot begin developing new vaccines that target new virus strains until the U.S. Centers for Disease Control and Prevention (CDC) creates a live-virus reference strain for these companies to work with, a process that could take several weeks.

Novavax says it can develop a prototype vaccine without the aid of a virus reference strain. Instead, it uses information the CDC posts in the Global Initiative on Sharing Avian Influenza Data (GISAID) database, launched in 2006 by a number of science institutes and universities worldwide (including WHO, the CDC and the Max Planck Institute for Informatics) to encourage data-sharing in response to the global spread of the H5N1 avian flu. The company claims its VLP approach allows it to manufacture a vaccine to match a particular virus strain in about three months.

Novavax says that during Phase IIa of seasonal flu vaccine testing, which began in May, it was able in the majority of people tested to surpass the FDA's requirements for producing enough antibodies to protect the body from the H3N2, H1N1 and B viruses—all of which were common enough a year ago to be used to develop flu vaccines for the 2008 to 2009 flu season. The vaccine was most effective against H3N2, increasing antibody titers (a measure how much antibody is produced after vaccination) fourfold in more than 81 percent of who received it, according to the company.



2 Comments

Add Comment
View
  1. 1. vonankh 08:06 PM 9/3/09

    This is indeed great news. I have been proposing to use this for a long time. Here in Norway, the government insist in buying 2 doses per person from Glaxo. They paid 650M NOKs and it will take 6 months to produce! Crazy, when considering it could take only 7 weeks to produce the same amount of non traditional vaccines!

    Also Replikins Ltd. have some similar peptide based vaccines in their pipeline...

    Reply | Report Abuse | Link to this
  2. 2. Len 09:06 PM 11/10/09

    Poor chickens! Even their unborn babies are tortured. Chickens are the most abused animals on the planet. Taken from their mothers before they even hatch, infected and killed by the vaccine industry, or for the meat/egg industry their beaks are cut off, they're crammed into filthy stench-filled sheds or battery cages in which they can't move, then suffocated or ground up alive when no longer "useful" to the factory farms or sent to slaughter to be scalded to death. Humans should be ashamed of their cruelty and greed. Flu is NOT a big deal and it's sanitation, not vaccines, that have defeated diseases. Factory farms on the other hand are intensive breeding grounds for diseases.

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

Tweets could not be retrieved at this time

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Email this Article

Building a Better Flu Vaccine--and Giving Chickens a Rest

X
Scientific American MIND iPad

Tap into your MIND

Get Both Print & Tablet Editions for one low price!

Subscribe Now >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X